CIPO Patents = 2

EPO Patents = 3

Forward Citations = 2

Loading Chart...

3 inventors (with patents filed for the assignee):

Pete O'Heeron (6 out of 21 patents)

Thomas E Ichim (5 out of 54 patents)

Kristin Comella (1 out of 2 patents)

4. Pete O'heeron (0 patent)

6 patents: Sort by Forward Citations

1. 12310991 - Stimulation of angiogenesis by fibroblast derived exosomes (2025-05-27),

2. 11975030 - Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof (2024-05-07),

3. 11959102 - Augmentation of fibroblast regenerative activity (2024-04-16),

4. 11878037 - Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis (2024-01-23),

5. 11819555 - Gene therapy for the regeneration of chondrocytes or cartilage type cells (2023-11-21),

6. 11732239 - Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof (2023-08-22),

Figene, LLC is a leading biotechnology company focused on genetic testing and personalized medicine. We provide innovative solutions for healthcare professionals and individuals looking to better understand their genetic makeup. Our advanced testing methods and cutting-edge technologies allow us to deliver accurate and reliable results to our clients. With a commitment to excellence and a passion for improving healthcare outcomes, Figene, LLC continues to push the boundaries of genetic testing and personalized medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

6 Patents

#724 in Houston, TX

#2,901 in Texas

#44,871 in US

Houston, TX, United States of America

Figene, LLC

Forward Citations = 2

3 inventors:

Pete O'Heeron (6 out of 21 patents)

Thomas E Ichim (5 out of 54 patents)

Kristin Comella (1 out of 2 patents)

4. Pete O'heeron (0 patent)

Please report any incorrect information to [email protected]

2 patents (CIPO):

Please report any incorrect information to [email protected]

3 patents (EPO):

Please report any incorrect information to [email protected]